Literature DB >> 20236390

Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Ina Han1, YiMei You, Jeffrey H Kordower, Scott T Brady, Gerardo A Morfini.   

Abstract

Abnormal expansion of a polyglutamine tract in huntingtin (Htt) protein results in Huntington's disease (HD), an autosomal dominant neurodegenerative disorder involving progressive loss of motor and cognitive function. Contrasting with the ubiquitous tissue expression of polyglutamine-expanded Htt, HD pathology is characterized by the increased vulnerability of specific neuronal populations within the striatum and the cerebral cortex. Morphological, biochemical, and functional characteristics of neurons affected in HD that might render these cells more vulnerable to the toxic effects of polyglutamine-Htt are covered in this review. The differential vulnerability of neurons observed in HD is discussed in the context of various major pathogenic mechanisms proposed to date, and in line with evidence showing a 'dying-back' pattern of degeneration in affected neuronal populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20236390      PMCID: PMC2890032          DOI: 10.1111/j.1471-4159.2010.06672.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  225 in total

1.  Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity.

Authors:  Barbara L Apostol; Katalin Illes; Judit Pallos; Laszlo Bodai; Jun Wu; Andrew Strand; Erik S Schweitzer; James M Olson; Aleksey Kazantsev; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2005-12-05       Impact factor: 6.150

2.  D1 dopamine receptor agonists mediate activation of p38 mitogen-activated protein kinase and c-Jun amino-terminal kinase by a protein kinase A-dependent mechanism in SK-N-MC human neuroblastoma cells.

Authors:  X Zhen; K Uryu; H Y Wang; E Friedman
Journal:  Mol Pharmacol       Date:  1998-09       Impact factor: 4.436

3.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

Authors:  R Luthi-Carter; A Strand; N L Peters; S M Solano; Z R Hollingsworth; A S Menon; A S Frey; B S Spektor; E B Penney; G Schilling; C A Ross; D R Borchelt; S J Tapscott; A B Young; J H Cha; J M Olson
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

Review 4.  Knock-in mouse models of Huntington's disease.

Authors:  Liliana B Menalled
Journal:  NeuroRx       Date:  2005-07

5.  Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.

Authors:  Shilpa Ramaswamy; Jodi L McBride; Christopher D Herzog; Eugene Brandon; Mehdi Gasmi; Raymond T Bartus; Jeffrey H Kordower
Journal:  Neurobiol Dis       Date:  2007-01-25       Impact factor: 5.996

6.  Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease.

Authors:  H Heinsen; U Rüb; M Bauer; G Ulmar; B Bethke; M Schüler; F Böcker; W Eisenmenger; M Götz; H Korr; C Schmitz
Journal:  Acta Neuropathol       Date:  1999-06       Impact factor: 17.088

7.  Polyglutamine expansion induces a protein-damaging stress connecting heat shock protein 70 to the JNK pathway.

Authors:  Karine Merienne; Dominique Helmlinger; Gordon R Perkin; Didier Devys; Yvon Trottier
Journal:  J Biol Chem       Date:  2003-02-21       Impact factor: 5.157

8.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.

Authors:  D M Mann; R Oliver; J S Snowden
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis.

Authors:  Laura Kennedy; Elizabeth Evans; Chiung-Mei Chen; Lyndsey Craven; Peter J Detloff; Margaret Ennis; Peggy F Shelbourne
Journal:  Hum Mol Genet       Date:  2003-10-21       Impact factor: 6.150

10.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

View more
  70 in total

1.  Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.

Authors:  Lori Zacharoff; Ivan Tkac; Qingfeng Song; Chuanning Tang; Patrick J Bolan; Silvia Mangia; Pierre-Gilles Henry; Tongbin Li; Janet M Dubinsky
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-02       Impact factor: 6.200

2.  Huntington's disease brain-derived small RNAs recapitulate associated neuropathology in mice.

Authors:  Jordi Creus-Muncunill; Anna Guisado-Corcoll; Veronica Venturi; Lorena Pantano; Georgia Escaramís; Marta García de Herreros; Maria Solaguren-Beascoa; Ana Gámez-Valero; Cristina Navarrete; Mercè Masana; Franc Llorens; Daniela Diaz-Lucena; Esther Pérez-Navarro; Eulàlia Martí
Journal:  Acta Neuropathol       Date:  2021-02-06       Impact factor: 17.088

Review 3.  Translating neurobehavioural endpoints of developmental neurotoxicity tests into in vitro assays and readouts.

Authors:  Christoph van Thriel; Remco H S Westerink; Christian Beste; Ambuja S Bale; Pamela J Lein; Marcel Leist
Journal:  Neurotoxicology       Date:  2011-10-12       Impact factor: 4.294

4.  Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.

Authors:  Nichole E LaPointe; Gerardo Morfini; Scott T Brady; Stuart C Feinstein; Leslie Wilson; Mary Ann Jordan
Journal:  Neurotoxicology       Date:  2013-05-24       Impact factor: 4.294

5.  Detection of axonal degeneration in a mouse model of Huntington's disease: comparison between diffusion tensor imaging and anomalous diffusion metrics.

Authors:  Rodolfo G Gatto; Allen Q Ye; Luis Colon-Perez; Thomas H Mareci; Anna Lysakowski; Steven D Price; Scott T Brady; Muge Karaman; Gerardo Morfini; Richard L Magin
Journal:  MAGMA       Date:  2019-02-15       Impact factor: 2.310

6.  Early Downregulation of p75NTR by Genetic and Pharmacological Approaches Delays the Onset of Motor Deficits and Striatal Dysfunction in Huntington's Disease Mice.

Authors:  Nuria Suelves; Andrés Miguez; Saray López-Benito; Gerardo García-Díaz Barriga; Albert Giralt; Elena Alvarez-Periel; Juan Carlos Arévalo; Jordi Alberch; Silvia Ginés; Verónica Brito
Journal:  Mol Neurobiol       Date:  2018-05-27       Impact factor: 5.590

Review 7.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

8.  Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Authors:  Marta Garcia-Miralles; Michal Geva; Jing Ying Tan; Nur Amirah Binte Mohammad Yusof; Yoonjeong Cha; Rebecca Kusko; Liang Juin Tan; Xiaohong Xu; Iris Grossman; Aric Orbach; Michael R Hayden; Mahmoud A Pouladi
Journal:  JCI Insight       Date:  2017-12-07

9.  Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains.

Authors:  Guang Bai; Iris Cheung; Hennady P Shulha; Joana E Coelho; Ping Li; Xianjun Dong; Mira Jakovcevski; Yumei Wang; Anastasia Grigorenko; Yan Jiang; Andrew Hoss; Krupal Patel; Ming Zheng; Evgeny Rogaev; Richard H Myers; Zhiping Weng; Schahram Akbarian; Jiang-Fan Chen
Journal:  Hum Mol Genet       Date:  2014-12-05       Impact factor: 6.150

Review 10.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.